Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Atara Biotherapeutics (ATRA) Equity Average (2022 - 2026)

Atara Biotherapeutics filings provide 5 years of Equity Average readings, the most recent being -$37.9 million for Q1 2026.

  • On a quarterly basis, Equity Average rose 50.24% to -$37.9 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$37.9 million, a 50.24% increase, with the full-year FY2025 number at -$67.9 million, down 7070.48% from a year prior.
  • Equity Average hit -$37.9 million in Q1 2026 for Atara Biotherapeutics, down from -$37.6 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $252.0 million in Q1 2022 to a low of -$104.6 million in Q2 2024.
  • Median Equity Average over the past 5 years was -$21.7 million (2023), compared with a mean of $28.0 million.
  • The widest YoY moves for Equity Average: up 64.41% in 2025, down 16606.5% in 2025.
  • Atara Biotherapeutics' Equity Average stood at $156.9 million in 2022, then plummeted by 84.58% to $24.2 million in 2023, then tumbled by 488.12% to -$93.9 million in 2024, then surged by 60.0% to -$37.6 million in 2025, then decreased by 0.9% to -$37.9 million in 2026.
  • The last three reported values for Equity Average were -$37.9 million (Q1 2026), -$37.6 million (Q4 2025), and -$35.8 million (Q3 2025) per Business Quant data.